Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
RELMADA THERAPEUTICS, INC. (RLMD)
|
Add to portfolio |
|
|
|
| Price: |
$22.94
| | Metrics |
| OS: |
30.1
|
M
| |
|
|
| Market cap: |
$690
|
M
| |
|
|
|
Net cash:
|
$119
|
M
| |
$3.94
|
per share
|
|
EV:
|
$572
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Jun-30-19 | Jun-30-18 | Jun-30-17 | Jun-30-16 |
| Revenues | -0.6 | -0.6 | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | -7.9% | 307.1% | | | | | | |
| Cost of goods sold | -657.7 | -251.4 | -121.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 657.1 | 250.8 | 121.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | -112227.0% | -39428.7% | -77791.9% | | | | | |
| Selling, general and administrative | | | | | | | | |
| Research and development | 113.3 | 90.6 | 36.0 | 7.9 | 7.0 | 2.9 | 1.3 | 6.2 |
| General and administrative | 47.9 | 35.1 | 24.9 | 7.2 | 5.7 | 4.0 | 5.9 | 10.0 |
| EBIT | -154.9 | -125.7 | -60.8 | -15.1 | -12.7 | -6.9 | -7.2 | -16.2 |
| EBIT margin | 26454.6% | 19764.3% | 38946.0% | | | | | |
| Pre-tax income | -157.0 | -125.8 | -59.5 | -15.0 | -17.3 | -9.0 | -6.3 | -3.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -157.0 | -125.8 | -59.5 | -15.0 | -17.3 | -9.0 | -6.3 | -3.0 |
| Net margin | 26821.2% | 19771.9% | 38061.1% | | | | | |
| |
| Diluted EPS | ($5.30) | ($7.16) | ($3.81) | ($1.62) | ($2.74) | ($0.71) | ($0.52) | ($0.26) |
| Shares outstanding (diluted) | 29.6 | 17.6 | 15.6 | 9.2 | 6.3 | 12.5 | 12.1 | 11.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|